Acknowledging that significant clinical benefit has been demonstrated with use of GLP-1 RAs in patients with T2DM, obesity, and cardiovascular disease—three of the top diseases that contribute to morbidity and mortality in the US and globally—the impacts of these diseases disproportionately affect Black and Hispanic patients, as well as communities with lower income and higher social determinants of health.15 This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.